Texas Red® is registered trademarks of Life Technologies. DyLight® is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries. Cy®and CyDye® are trademarks of GE Healthcare Limited.
如需求购,请扫描以下二维码
——————
参考文献:
1 Lu, H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Bioscience trends, doi:10.5582/bst.2020.01020 (2020).
2 Lo, M. K. et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Scientific reports 7, 43395, doi:10.1038/srep43395 (2017).
3 Sheahan, T. P. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science translational medicine 9, doi:10.1126/scitranslmed.aal3653 (2017).
4 Warren, T. K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381-385, doi:10.1038/nature17180 (2016).
5 Sheahan, T. P. et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature communications 11, 222, doi:10.1038/s41467-019-13940-6 (2020).
6 Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, doi:10.1038/s41422-020-0282-0 (2020).
7 Zhu, N. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England journal of medicine, doi:10.1056/NEJMoa2001017 (2020).
8 Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, doi:10.1038/s41586-020-2012-7 (2020).
9 Holshue, M. L. et al. First Case of 2019 Novel Coronavirus in the United States. The New England journal of medicine, doi:10.1056/NEJMoa2001191 (2020).
10 Cheng, Y. et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 24, 44-46, doi:10.1007/s10096-004-1271-9 (2005).
11 Luke, T. C., Kilbane, E. M., Jackson, J. L. & Hoffman, S. L. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Annals of internal medicine 145, 599-609, doi:10.7326/0003-4819-145-8-200610170-00139 (2006).
12 Hung, I. F. et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 52, 447-456, doi:10.1093/cid/ciq106 (2011).
13 Zhou, B., Zhong, N. & Guan, Y. Treatment with convalescent plasma for influenza A (H5N1) infection. The New England journal of medicine 357, 1450-1451, doi:10.1056/NEJMc070359 (2007).
14 Mair-Jenkins, J. et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. The Journal of infectious diseases 211, 80-90, doi:10.1093/infdis/jiu396 (2015).
15 Corti, D. et al. Tackling influenza with broadly neutralizing antibodies. Current opinion in virology 24, 60-69, doi:10.1016/j.coviro.2017.03.002 (2017).
16 Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450-454, doi:10.1038/nature02145 (2003).
17 Raj, V. S. et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495, 251-254, doi:10.1038/nature12005 (2013).
18 Hoffmann, M. et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv, 2020.2001.2031.929042, doi:10.1101/2020.01.31.929042 (2020).
19 Letko, M. & Munster, V. Functional assessment of cell entry and receptor usage for lineage B β-coronaviruses, including 2019-nCoV. bioRxiv, 2020.2001.2022.915660, doi:10.1101/2020.01.22.915660 (2020).
20 Yeager, C. L. et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature 357, 420-422, doi:10.1038/357420a0 (1992).
21 Menachery, V. D. et al. Trypsin treatment unlocks barrier for zoonotic bat coronaviruses infection. Journal of virology, doi:10.1128/JVI.01774-19 (2019).
22 Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, doi:10.1016/S0140-6736(20)30183-5 (2020).
23 Wong, C. K. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clinical and experimental immunology 136, 95-103, doi:10.1111/j.1365-2249.2004.02415.x (2004).
24 Mahallawi, W. H., Khabour, O. F., Zhang, Q., Makhdoum, H. M. & Suliman, B. A. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine 104, 8-13, doi:10.1016/j.cyto.2018.01.025 (2018).
25 Li, Y. et al. Coronavirus Infections in the Central Nervous System and Respiratory Tract Show Distinct Features in Hospitalized Children. Intervirology 59, 163-169, doi:10.1159/000453066 (2016).
26 Yu, S.-Y. et al. Gene expression profiles in peripheral blood mononuclear cells of SARS patients. World J Gastroenterol 11, 5037-5043, doi:10.3748/wjg.v11.i32.5037 (2005).
27 Zuo, J., Stohlman, S. A., Parra, G. I. & Bergmann, C. C. IL-15 independent maintenance of virus-specific CD8(+) T cells in the CNS during chronic infection. Journal of neuroimmunology 207, 32-38, doi:10.1016/j.jneuroim.2008.11.005 (2009).
28 Ding, L. et al. CD69+NK cells contribute to the murine hepatitis virus strain 3-induced murine hepatitis. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 33, 505-510, doi:10.1007/s11596-013-1150-7 (2013).
29 Yeung, M. L. et al. MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2. 1, 16004, doi:10.1038/nmicrobiol.2016.4 (2016).
30 Barnard, D. L. et al. Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. Antiviral Res 71, 53-63, doi:10.1016/j.antiviral.2006.03.001 (2006).
31 Funk, C. J. et al. Infection of human alveolar macrophages by human coronavirus strain 229E. The Journal of general virology 93, 494-503, doi:10.1099/vir.0.038414-0 (2012).
32 Liu, M. et al. Differences in inflammatory marker patterns for adult community-acquired pneumonia patients induced by different pathogens. The clinical respiratory journal 12, 974-985, doi:10.1111/crj.12614 (2018).
33 Vinores, S. A. et al. Blood-retinal barrier breakdown in experimental coronavirus retinopathy: association with viral antigen, inflammation, and VEGF in sensitive and resistant strains. Journal of neuroimmunology 119, 175-182, doi:10.1016/s0165-5728(01)00374-5 (2001).
34 Darwish, I., Mubareka, S. & Liles, W. C. Immunomodulatory therapy for severe influenza. Expert review of anti-infective therapy 9, 807-822, doi:10.1586/eri.11.56 (2011).
35 Russell, C. D., Millar, J. E. & Baillie, J. K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet, doi:https://doi.org/10.1016/S0140-6736(20)30317-2 (2020).